This text deals with the implications of probable future disease-modifying Alzheimer's disease (AD) treatment on diagnostic testing. It is widely presumed that disease-modifying treatments with ␥ -and ␤ -secretase inhibitors or vaccination regimes will have optimal effect if initiated early in the disease process [1, 2] . Much focus has thus been directed on patients with mild cognitive impairment (MCI), a syndrome characterized by cognitive impairment beyond the age-adjusted norm, but not severe enough to fulfill the criteria for dementia [3] . The annual rate of AD diagnosis in amnestic MCI patients is about 15% [4, 5] . However, some MCI cases have a benign clinical course with no symptom progression, while others prove to have other types of dementia. A primary diagnostic challenge to clinicians will therefore be to identify MCI patients with incipient AD, requiring an immediate start of treatment. For this purpose, several studies have tested the diagnostic accuracy of imaging techniques and cerebrospinal fluid (CSF) levels of ␤ -amyloid 1-42 and in an early stage of the disease [6] [7] [8] [9] [10] [11] [12] . These biomarkers have good or excellent sensitivity and specificity of 85-95% for incipient AD in MCI populations. While these figures are of interest to researchers, publichealth policymakers and the diagnostics industry, they are of little use to clinicians. Sensitivity and specificity look backward at results gathered over time [13] , but clinicians have to interpret test results to those tested with
This text deals with the implications of probable future disease-modifying Alzheimer's disease (AD) treatment on diagnostic testing. It is widely presumed that disease-modifying treatments with ␥ -and ␤ -secretase inhibitors or vaccination regimes will have optimal effect if initiated early in the disease process [1, 2] . Much focus has thus been directed on patients with mild cognitive impairment (MCI), a syndrome characterized by cognitive impairment beyond the age-adjusted norm, but not severe enough to fulfill the criteria for dementia [3] . The annual rate of AD diagnosis in amnestic MCI patients is about 15% [4, 5] . However, some MCI cases have a benign clinical course with no symptom progression, while others prove to have other types of dementia. A primary diagnostic challenge to clinicians will therefore be to identify MCI patients with incipient AD, requiring an immediate start of treatment. For this purpose, several studies have tested the diagnostic accuracy of imaging techniques and cerebrospinal fluid (CSF) levels of ␤ -amyloid 1-42 and in an early stage of the disease [6] [7] [8] [9] [10] [11] [12] . These biomarkers have good or excellent sensitivity and specificity of 85-95% for incipient AD in MCI populations. While these figures are of interest to researchers, publichealth policymakers and the diagnostics industry, they are of little use to clinicians. Sensitivity and specificity look backward at results gathered over time [13] , but clinicians have to interpret test results to those tested with is the ratio of true negatives to the total number of negative test results. While sensitivity and specificity depend on test characteristics in the laboratory, predictive values are influenced in a very powerful manner by the prevalence of the disease among those tested. When testing patients with MCI, which is a common patient group at the memory clinics of today, CSF biomarkers for AD have good or excellent predictive values of 80-95% [6, 10] , and hence they are clinically useful in this setting.
However, the neurodegenerative process is likely well under way in MCI patients with incipient AD. Indeed, it probably starts many years before the debut of symptoms and a large part of the neural loss may actually have taken place already before symptom onset. Treating MCI patients admitted to memory clinics will therefore only constitute a secondary prevention of AD. If effective disease-modifying treatment becomes available, it will give rise to an urge for primary prevention, trying to avoid the development of disease. Being presymptomatic, such prevention can only be achieved by utilizing a screening program in the middle-aged or in the young elderly.
General Population Screening
Which are the prerequisites of such a screening program, and how must effective diagnostic tools be developed for such purposes? The answers to these questions will depend partly on the efficacy, tolerability and cost of the putative treatments. However, as reasoned above, establishing the prevalence of incipient AD in the screened population will also be crucial. Since the exact presymptomatic duration is unknown, this is prone to speculation. In the following, we calculate with an average disease period of 5-10 years before any cognitive symptoms. This is supported by imaging as well as CSF biomarker studies [14] [15] [16] . Studies in presymptomatic carriers of familial AD mutations suggest that this period may be even longer [17] . The prevalence of dementia in people 70 years old varies in different regions, but is around 3.3% in Europe and North America, where after it increases to 25-30% in people aged 1 85 years [18] . The most common cause of dementia is AD, representing around 60% of dementia cases [19] . The prevalence of presymptomatic AD in people aged 60 years may therefore be estimated to be 2%. Adapting a diagnostic test with excellent 95% sensitivity and 95% specificity in this population will result in a very high NPV (99.9%) but a low PPV (28%) ( table 1 ). This means that the test will be useful for ruling out incipient AD, but a positive answer will still in most cases indicate a person without AD. A diagnostic test with 99% sensitivity and 99% specificity, i.e. far better than the currently available tests including pathological examination, will only result in a PPV of 67%, meaning that one third of patients tested positive will not have AD ( table 2 ) . Although troublesome, these are figures approaching the efficacy of breast cancer screening, where the rate of false positives has been approximated to one third [20] .
So, how can we optimize the clinical usefulness of diagnostic tests with this accuracy? If a general screening program in 60-year-olds is an option, there will be many false positives, indicated as in need of treatment. This might be acceptable if the treatment is harmless and inexpensive. As an example, it is generally regarded acceptable that most people who take cholesterol-lowering drugs on the basis of plasma cholesterol values above a certain cut-point will have no individual benefit of the treatment in the absence of other risk factors for cardiovascular disease [21] . If the treatment has significant side effects or is very expensive, care must be taken to implement a follow-up test of high specificity to confirm a positive test result. It is at present unclear what such an evaluation might exactly look like in presymptomatic, biomarker-positive individuals, warranting more research. Another way around the problem would be to postpone screening including only older individuals, where the prevalence is higher. But this will delay diagnosis in younger patients who, it might be argued, are in most need of treatment in order to preserve working capability and social function. Since AD prevalence increases with age, screening would probably be repetitive, much like screening for breast cancer or cervix cancer is done today. Calculating with a 10-year latency phase, a screening program could for example consist of testing every 3rd to 7th year from the age of 60. However, in lower age categories, efforts must still be taken to enrich test populations with AD cases.
Specific Population Screening
How about considering APOE genotypes? The APOE 4 carrier rate in the general population is approximately 26% [22] . One study examining the carrier rate in AD patients and healthy controls in different ages found an APOE 4 carrier rate of 15% in 60-year-old healthy controls and 50% in 70-year-old AD patients [23] . Thus, a group of 10,000 symptom-free 60-year-old persons will include 1,500 APOE 4 carriers, and 100 of these will have incipient AD (prevalence 2% and APOE 4 carrier rate 50%). Using a diagnostic test with 99% sensitivity and 99% specificity on these individuals yields a PPV of 88% and an NPV of 99.9% ( table 3 ) . The major hitch with this strategy is of course the exclusion of the 50% of incipient AD patients aged 60 years not carrying the APOE 4 allele. If such a screening strategy should be successful it therefore requires including all individuals in the following screening rounds, irrespectively of APOE genotype.
In sum, it is not unlikely that we will have access to disease-modifying treatments of AD within a reasonably near future. How these treatments should be applied will invoke political and medical questions of considerable importance and difficulty. Powerful diagnostic tests will undoubtedly be needed, but one must also bear in mind the limitations of these tests when used in the general population. Even biomarkers with very high sensitivity and specificity must be limited to specific and well-defined clinical settings. Due to their wide implications, these questions need to be addressed well ahead by researchers developing biomarkers for neurodegenerative disorders. The total number of studied subjects is 15,000, representing the number of APOE 4 carriers in a population of 100,000 symptom-free 60-year-old persons.
